| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.2 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.2 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.2 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | Vinorelbine | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |